ENDPOINTS

Merck and Hengrui strike $2B deal for Lipoprotein(a) drug

Merck has struck a licensing deal for a cardiovascular drug with Jiangsu Hengrui Pharmaceuticals, the latest in a flood of China deals being made by US and European multinationals. Under the deal, Merck will get ...

Mar 25, 2025 - 11:33
 0
Merck and Hengrui strike $2B deal for Lipoprotein(a) drug
Merck has struck a licensing deal for a cardiovascular drug with Jiangsu Hengrui Pharmaceuticals, the latest in a flood of China deals being made by US and European multinationals. Under the deal, Merck will get ...
Read More

Tags:

Previous Article

Hillstar Bio raises $67M for immunology drugs

Next Article

Ocean dumping – or a climate solution? A growing industry bets on the ocean to c...

Related Posts

BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen

BridgeBio oncology spinout to go public via combination...

Feb 28, 2025  0

AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron

AstraZeneca broadens presence in China, promising $8B+ ...

Mar 21, 2025  0

ITM reports more Phase 3 radiopharma data in challenge to Novartis’ Lutathera

ITM reports more Phase 3 radiopharma data in challenge ...

Mar 6, 2025  0